KD01 for advanced gynecologic cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called KD01 for women with advanced gynecologic cancers (like cervical or endometrial cancer) that haven't responded to other treatments. It also has a separate part for younger women who want to preserve their fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a gynecologic cancer (like cervical or endometrial) that did not get better with standard treatment.
- You are between 18 and 75 years old (or up to 40 for the fertility-preservation part).
- You are in fairly good health, able to care for yourself, and expected to live at least 3 more months.
- Your blood counts, liver, kidney, and heart function must be within safe limits.
- You cannot be pregnant, and you must use birth control for 3 months after the last dose.
- You cannot have serious heart problems, active infections, or certain other medical conditions listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
This early-phase study tests whether KM1 is safe and can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that has come back or not responded to standard treatment. It may help people who have limited options, but eligibility is strict to keep participants safe.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
This trial tests an experimental cell treatment called GK01 for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if it can help shrink tumors or slow their growth.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.